Targets › CUL4A
11 programs from 9 companies in 225 trials: 134 Phase 2, 57 Phase 1, 33 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Feb 2027.
Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. (UniProt, Q13619)
Open in Phaseline: the race on CUL4A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | DS Stage I Multiple Myeloma; Multiple Myeloma | Feb 2027 |
| Incyte | Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma; Newly Diagnosed … | Apr 2027 |
| Beijing InnoCare Pharma Tech | Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | DLBCL | Apr 2027 |
| University of Arkansas | Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma; Myeloma | Aug 2027 |
| Bristol-Myers Squibb | Iberdomide CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma; Lymphoma, B-Cell; Newly Diagnosed Multiple Myeloma; Smoldering Plasma Cell Myeloma … | Nov 2027 |
| Shandong New Time Pharmaceutical | Pomalidomide (F182112) CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM); Relapsed or Refractory Multiple Myeloma; Systemic Lupus Erythematosus (SLE); Multiple Myeloma … | Dec 2027 |
| CellCentric | Pomalidomide (CCS1477) CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Multiple Myeloma Refractory | Nov 2029 |
| Roche | Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 3 | Relapsed or Refractory Follicular Lymphoma; Follicular Lymphoma | Dec 2029 |
| National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor | CRBN, DDB1, CUL4A, RBX1 | Phase 2 | Fetal Hemoglobin | – |
| Roche | Iberdomide (CC-220) CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 1 | Multiple Myeloma; Non-Hodgkin Lymphoma | Jul 2028 |
| Bristol-Myers Squibb | Iberdomide (BMS-986382) CRL4(CRBN) E3 ubiquitin ligase modulator | CRBN, DDB1, CUL4A, RBX1 | Phase 1 | Multiple Myeloma | Aug 2028 |
Multiple Myeloma (54) Plasma Cell Myeloma (7) Follicular Lymphoma (6) Mantle Cell Lymphoma (6) DLBCL (5) Recurrent Multiple Myeloma (4) Diffuse Large B-cell Lymphoma (4) DS Stage I Multiple Myeloma (4) Multiple Myeloma in Relapse (4) Myeloma (3) Fetal Hemoglobin (3) Smoldering Plasma Cell Myeloma (3)
mixed (8), small molecule (3)
Bristol-Myers Squibb (2) Roche (2) University of Arkansas (1) National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (1) Incyte (1) National Cancer Institute (NCI) (1) Shandong New Time Pharmaceutical (1) Beijing InnoCare Pharma Tech (1) CellCentric (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.